Brief: Eisai Will Request Reconsideration Of Initial Decision For Lecanemab In Australia
17/10/2024 24:32
Oct 16 (Reuters) - BioArctic AB BIOAb.ST :
* EISAI WILL REQUEST RECONSIDERATION OF INITIAL DECISION FOR
LECANEMAB IN AUSTRALIA
Source text for Eikon: ID:nWkr8cSQvG
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln